Latest & greatest articles for bronchiolitis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on bronchiolitis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on bronchiolitis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Bronchiolitis

Bronchiolitis is mainly caused by the respiratory syncytial virus (RSV). The virus travels down to the bronchioles in the lungs causing them to become inflamed making it difficult to breath.

Almost every child will be infected with RSV by the time they reach two years. Adults can also contract the virus, typically during winter months.

In mild cases bronchiolitis will clear up without treatment. The virus that causes bronchiolitis travels through tiny droplets of liquid and can be passed through the air or contracted by touching infected surfaces.

Symptoms include: Sore throat, dry cough, blocked nose and aches and pains throughout the body.

Although there is no cure for chronic bronchiolitis research and clinical studies on bronchiolitis suggest that some lifestyle changes can ease symptoms: avoid smoking, eat a healthy diet and maintain regular exercise. In extreme cases steroids can be prescribed to help minimise inflammation.

Read more on medications used to treat bronchiolitis and the causes of the virus.

Top results for bronchiolitis

81. Racemic adrenaline and inhalation strategies in acute bronchiolitis. Full Text available with Trip Pro

Racemic adrenaline and inhalation strategies in acute bronchiolitis. Acute bronchiolitis in infants frequently results in hospitalization, but there is no established consensus on inhalation therapy--either the type of medication or the frequency of administration--that may be of value. We aimed to assess the effectiveness of inhaled racemic adrenaline as compared with inhaled saline and the strategy for frequency of inhalation (on demand vs. fixed schedule) in infants hospitalized with acute (...) bronchiolitis.In this eight-center, randomized, double-blind trial with a 2-by-2 factorial design, we compared inhaled racemic adrenaline with inhaled saline and on-demand inhalation with fixed-schedule inhalation (up to every 2 hours) in infants (<12 months of age) with moderate-to-severe acute bronchiolitis. An overall clinical score of 4 or higher (on a scale of 0 to 10, with higher scores indicating more severe illness) was required for study inclusion. Any use of oxygen therapy, nasogastric-tube feeding

2013 NEJM Controlled trial quality: predicted high

82. Breo Ellipta (fluticasone furoate and vilanterol inhalation powder) - For the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema

Breo Ellipta (fluticasone furoate and vilanterol inhalation powder) - For the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema Drug Approval Package: Brand Name (Generic Name) NDA # Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Ellipta (fluticasone furoate and vilanterol trifenatate) Inhalation Powder Company: GlaxoSmithKline

2013 FDA - Drug Approval Package

83. Antibiotics for persistent cough or wheeze following acute bronchiolitis in children. Full Text available with Trip Pro

Antibiotics for persistent cough or wheeze following acute bronchiolitis in children. Bronchiolitis is a common acute respiratory infectious condition, with a high prevalence worldwide. It is a clinically diagnosed syndrome, manifested by tachypnoea (rapid breathing), with crackles or wheeze in young children. In the acute phase of bronchiolitis (< 14 days), antibiotics have only been recommended when a secondary bacterial infection is suspected. Although bronchiolitis is usually a self (...) -limiting condition, a number of children have persistent respiratory symptoms such as cough and wheezing in post-acute bronchiolitis, and they present or re-present to secondary care.To determine the effectiveness of antibiotics compared to a control (no treatment or placebo) for persistent respiratory symptoms (within six months), following acute bronchiolitis.The following databases were searched, The Cochrane Airways Group Register of Trials, Cochrane Central Register of Controlled Trials (CENTRAL

2012 Cochrane

84. Azithromycin Therapy in Hospitalized Infants with Acute Bronchiolitis is Not Associated with Better Clinical Outcomes: A Randomized, Double-Blinded, and Placebo-Controlled Clinical Trial (Abstract)

Azithromycin Therapy in Hospitalized Infants with Acute Bronchiolitis is Not Associated with Better Clinical Outcomes: A Randomized, Double-Blinded, and Placebo-Controlled Clinical Trial To test the hypothesis that azithromycin reduces the length of hospitalization and oxygen requirement in infants with acute viral bronchiolitis (AB).We performed a randomized, double-blinded, placebo-controlled trial in southern Brazil, from 2009 to 2011. Infants (<12 months of age) hospitalized with AB were

2012 EvidenceUpdates Controlled trial quality: predicted high

85. Gemifloxacin for the treatment of community-acquired pneumonia and acute exacerbation of chronic bronchitis: a meta-analysis of randomized controlled trials

Gemifloxacin for the treatment of community-acquired pneumonia and acute exacerbation of chronic bronchitis: a meta-analysis of randomized controlled trials Gemifloxacin for the treatment of community-acquired pneumonia and acute exacerbation of chronic bronchitis: a meta-analysis of randomized controlled trials Gemifloxacin for the treatment of community-acquired pneumonia and acute exacerbation of chronic bronchitis: a meta-analysis of randomized controlled trials Zhang L, Wang R, Falagas ME (...) , Chen LA, Liu YN CRD summary This review concluded that the effectiveness of gemifloxacin was equivalent or superior to that of other antibiotics for community-acquired pneumonia and acute exacerbations of chronic bronchitis. However, there was significantly higher risk of rash and diarrhoea compared to other quinolones. Limitations in the evidence base and data analysis suggest that these conclusions should be regarded as provisional. Authors' objectives To evaluate the effectiveness and safety

2012 DARE.

86. Hospitalisation for bronchiolitis in infants is more common after elective caesarean delivery (Abstract)

Hospitalisation for bronchiolitis in infants is more common after elective caesarean delivery The authors previously reported an increased risk of hospitalisation for acute lower respiratory infection up to age 2 years in children delivered by elective caesarean section. In view of increasing rates of elective caesarean delivery, this association warranted further investigation.To examine associations between the number of hospital admissions for bronchiolitis and pneumonia and elective (...) caesarean delivery.Retrospective population-based data linkage cohort study of 212 068 non-Aboriginal singleton births of 37-42 weeks gestation.Negative binomial regression was used to examine associations between mode of delivery and hospitalisations for both bronchiolitis and pneumonia in children aged <12 months and 12-23 months. Models were adjusted for obstetric and known risk factors.16% of children were delivered by elective caesarean section (n=33 421). In adjusted analysis, compared

2012 EvidenceUpdates

87. Helium-oxygen therapy for infants with bronchiolitis: a randomized controlled trial

Helium-oxygen therapy for infants with bronchiolitis: a randomized controlled trial PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

2012 PedsCCM Evidence-Based Journal Club

88. Chinese medicinal herbs for acute bronchitis. (Abstract)

Chinese medicinal herbs for acute bronchitis. Acute bronchitis is one of the most common diagnoses made by primary care physicians. It is traditionally treated with antibiotics (although the evidence for their effectiveness is weak, and modest at best) and other even less effective treatments. Chinese medicinal herbs have also been used as a treatment.This review aimed to summarise the existing evidence on the comparative effectiveness and safety of Chinese medicinal herbs for treating (...) herbs for acute bronchitis. Trial design limitations of the individual studies meant that we could not draw any conclusions about the benefits of Chinese herbs for acute bronchitis. In addition, the safety of Chinese herbs is unknown due to the lack of toxicological evidence for these herbs, although adverse events were reported in some case reports.

2012 Cochrane

89. Antibiotics for Acute Bronchitis

Antibiotics for Acute Bronchitis Antibiotics for Acute Bronchitis – TheNNTTheNNT Antibiotics for the Treatment of Acute Bronchitis in Adults 37 for side effects In Summary, for those who received the antibiotics: Benefits in NNT 100% saw no benefit 18% were helped by a reduction in symptoms, including cough None were helped (overall) 1 in 6 were helped (no cough at follow up) Harms in NNT 2.6% were harmed by medication side effects 1 in 37 were harmed (minor adverse effects at follow up) View (...) As: NNT % Source: Efficacy Endpoints: Clinical improvement or cure Harm Endpoints: Reduction in cough Narrative: Acute bronchitis is defined as a cough-related illness lasting 1-3 weeks with or without sputum in an individual without chronic lung disease and a normal chest radiograph. It is one of the most common conditions for which patients consult a physician and the most common reasons for seeking care are symptom severity, duration, and interference with daily activities. Less than 10% of cases

2012 theNNT

90. n Infants Younger Than 24 Months Old and With Bronchiolitis, Does Nebulized Epinephrine Improve Clinical Status?

n Infants Younger Than 24 Months Old and With Bronchiolitis, Does Nebulized Epinephrine Improve Clinical Status? SystematicReviewSnapshot TAKE-HOME MESSAGE Nebulized epinephrine decreases the risk of hospitalization of infants younger than 24 months and with bronchiolitis when presenting within the ?rst 24 hours of illness. METHODS DATA SOURCE The authors searched MEDLINE, EMBASE, Cochrane Central Regis- ter of Controlled Trials (CENTRAL), Scopus, PubMed, Lilacs, Iran MedEx, the Cochrane (...) Library, and Global Health, inclu- sive through September 2010; key references from included articles were reviewed. STUDY SELECTION The studies included were ran- domized controlled trials involv- ing children younger than 24 months, with bronchiolitis (de- ?ned as a ?rst episode of wheezing, respiratory distress, and clinical evidence of respira- tory infection), and receiving nebulized epinephrine compared with placebo or other therapy. Critically ill and arti?cially venti- lated patients were

2012 Annals of Emergency Medicine Systematic Review Snapshots

91. Do Febrile Infants Aged 60 to 90 Days With Bronchiolitis Require a Septic Evaluation?

Do Febrile Infants Aged 60 to 90 Days With Bronchiolitis Require a Septic Evaluation? SystematicReviewSnapshot TAKE-HOME MESSAGE Febrile infants younger than 90 days and with bronchiolitis have very low rates of serious bacterial infection. METHODS DATA SOURCE The authors searched the Na- tional Library of Medicine Medline database (to December 2010). In addition, the bibliographies of these studies were searched for studies not otherwise identi?ed. STUDY SELECTION Studies were selected (...) if they re- ported the incidence of site-spe- ci?c, concomitant serious bacterial infection in the setting of fever and clinical bronchiolitis or documented respiratory syncytial virus infection. Studies also had to report the type of culture collected and contain age-speci?c data for infants younger than 60 to 90 days. DATA EXTRACTION AND SYNTHESIS The authors extracted the event rates for bacteremia, meningitis, and urinary tract infection. Urinary tract infections were diagnosed by urine culture. Two

2012 Annals of Emergency Medicine Systematic Review Snapshots

92. Systematic review and meta-analysis: Epinephrine for acute bronchiolitis, but not steroids alone, reduces hospital admissions

Systematic review and meta-analysis: Epinephrine for acute bronchiolitis, but not steroids alone, reduces hospital admissions Epinephrine for acute bronchiolitis, but not steroids alone, reduces hospital admissions | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password (...) For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Epinephrine for acute bronchiolitis, but not steroids alone, reduces hospital admissions Article Text Therapeutics Systematic review and meta-analysis Epinephrine for acute

2012 Evidence-Based Medicine

93. Non-invasive ventilation as primary ventilatory support for infants with severe bronchiolitis

Non-invasive ventilation as primary ventilatory support for infants with severe bronchiolitis PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

2011 PedsCCM Evidence-Based Journal Club

94. Constrictive bronchiolitis in soldiers returning from Iraq and Afghanistan. Full Text available with Trip Pro

Constrictive bronchiolitis in soldiers returning from Iraq and Afghanistan. In this descriptive case series, 80 soldiers from Fort Campbell, Kentucky, with inhalational exposures during service in Iraq and Afghanistan were evaluated for dyspnea on exertion that prevented them from meeting the U.S. Army's standards for physical fitness.The soldiers underwent extensive evaluation of their medical and exposure history, physical examination, pulmonary-function testing, and high-resolution computed (...) samples were abnormal, with 38 soldiers having changes that were diagnostic of constrictive bronchiolitis. In the remaining 11 soldiers, diagnoses other than constrictive bronchiolitis that could explain the presenting dyspnea were established. All soldiers with constrictive bronchiolitis had normal results on chest radiography, but about one quarter were found to have mosaic air trapping or centrilobular nodules on chest CT. The results of pulmonary-function and cardiopulmonary-exercise testing were

2011 NEJM

95. Inhaled Epinephrine, Steroids for Bronchiolitis

Inhaled Epinephrine, Steroids for Bronchiolitis Inhaled Epinephrine, Steroids for Bronchiolitis – TheNNTTheNNT Inhaled Epinephrine with or without Steroids for Bronchiolitis 15 for admission In Summary, for those who received the epinephrine with/without the steroids: Benefits in NNT 94.1% saw no benefit 5.9% were helped (epinephrine alone) by preventing hospital admission (day 1) 1 in 17 were helped (epinephrine alone) (hospitalization prevented, day 1) Harms in NNT None were harmed (...) by medication side effects None were harmed (medication side effects) View As: NNT % Source: Efficacy Endpoints: Admission Rate (Day 1) Harm Endpoints: None Narrative: Bronchiolitis, a viral respiratory infection in the first 2 years of life (most commonly caused by respiratory syncytial virus) often leads to significant use of healthcare resources. Optimal management strategies remain unclear, including pharmacotherapy for wheezing and shortness of breath. This Cochrane review identified and assessed six

2011 theNNT

96. Steroids and bronchodilators for acute bronchiolitis in the first two years of life: systematic review and meta-analysis

Steroids and bronchodilators for acute bronchiolitis in the first two years of life: systematic review and meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2011 DARE.

97. Nebulized Hypertonic Saline for Bronchiolitis

Nebulized Hypertonic Saline for Bronchiolitis Nebulized Hypertonic Saline for Bronchiolitis – TheNNTTheNNT Nebulized Hypertonic Saline for Bronchiolitis in Infants 1 less hospital day IMPORTANT! In Summary, for those who received the nebulized hypertonic saline: Benefits in NNT Hospitalized infants were helped by a 1-day decrease in their hospital stay Harms in NNT None were harmed View As: NNT % Source: Efficacy Endpoints: Duration of Hospital Stay, Decrease in Clinical Severity Scores (...) , Decrease in Admission Rates Harm Endpoints: Tachycardia, Hypertension, Pallor, Tremor, Nausea, and Vomiting Narrative: Acute bronchiolitis is the one of the most common respiratory infections in infants. It affects the lower respiratory tract and is usually caused by a virus, with respiratory syncytial virus (RSV) being the most common pathogen. It is estimated that nearly all infants are infected with RSV and that between 1 and 2% of these develop symptoms severe enough to warrant admission. While

2011 theNNT

98. WITHDRAWN: Inhaled corticosteroids during acute bronchiolitis in the prevention of post-bronchiolitic wheezing. (Abstract)

WITHDRAWN: Inhaled corticosteroids during acute bronchiolitis in the prevention of post-bronchiolitic wheezing. Acute bronchiolitis in infants and young children is associated with long-term airway disease also known as post-bronchiolitic wheezing. Two major hypotheses have been proposed to explain the association between bronchiolitis and PBW. The first hypothesis considers bronchiolitis to be the first manifestation of recurrent wheezing in infants and children who are susceptible (...) to obstructive airway disease. The second hypothesis suggests that the infection and concomitant inflammatory reaction in the acute phase leads to airway epithelium injury resulting in long-term obstructive airway disease. In line with the latter hypothesis, corticosteroids may have a beneficial effect on the prevention of post-bronchiolitic wheezing.The objective of this review was to evaluate the effect of inhaled corticosteroids, started during the acute phase of bronchiolitis, on the prevention of post

2011 Cochrane

99. Steam inhalation or humidified oxygen for acute bronchiolitis in children up to three years of age. (Abstract)

Steam inhalation or humidified oxygen for acute bronchiolitis in children up to three years of age. Acute bronchiolitis is a common respiratory infection and a major cause of morbidity in young children. It is treated with bronchodilators (for example, salbutamol), corticosteroids or humidified air (steam inhalation or cool mist). Steam inhalation is preferred in low-income countries as it is inexpensive and easily available. It is thought to act as a secretolytic agent to lighten secretions (...) (1981 to March 2010), AMED (1985 to March 2010), Web of Science (2000 to March 2010) and LILACS (1982 to March 2010).Randomised controlled trials involving children up to three years old with bronchiolitis comparing steam inhalation (or cool mist) or humidified oxygen against bronchodilators, corticosteroids or placebo; alone or in combination.Two review authors independently assessed trial quality and extracted data.Only one study (156 children aged between seven weeks and 24 months with signs

2011 Cochrane

100. Palivizumab for immunoprophylaxis of respiratory syncitial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses

Palivizumab for immunoprophylaxis of respiratory syncitial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk (...) infants and young children: a systematic review and additional economic modelling of subgroup analyses Wang D, Bayliss S, Meads C Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Wang D, Bayliss S, Meads C. Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic

2011 Health Technology Assessment (HTA) Database.